Drugs / PLN-101095
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06270706 | Aug 2023 → Jun 2030 expected | — | Pliant Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-08-18 | Pliant Therapeutics, Inc. | Regulatory Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors pliantrx.com ↗
Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095 |
| 2026-05-11 | Pliant Therapeutics, Inc. | Results Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results pliantrx.com ↗
We were excited to highlight encouraging recent data from the Phase 1a trial of PLN-101095 at AACR showing deepening responses and increasing time on treatment. |
| 2026-04-18 | Pliant Therapeutics, Inc. | Results Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting pliantrx.com ↗
As of the data cutoff date, the median time on treatment for the three confirmed responders was 19 months, who experienced an average baseline target tumor reduction of 89%. |
| 2025-12-04 | Pliant Therapeutics, Inc. | Results Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors pliantrx.com ↗
Across the three highest dose cohorts, there were four responders consisting of one confirmed complete response (CR) and three partial responses (PR) (two confirmed, one unconfirmed) out of the 10 secondary ICI refractory patients. |
| 2025-05-08 | Pliant Therapeutics, Inc. | Results Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results pliantrx.com ↗
Additionally, progress was made in our oncology program with initial data from our Phase 1 dose escalation trial of PLN-101095 demonstrating antitumor activity, including confirmed partial responses, in a variety of solid tumors. |
| 2025-03-17 | Pliant Therapeutics, Inc. | Results Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors pliantrx.com ↗
Interim results demonstrated PLN-101095 anti-tumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily (BID) dose, representing a 50% objective response rate (ORR) at the highest dose tested to date. |
| 2023-11-06 | Pliant Therapeutics, Inc. | Results Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1 pliantrx.com ↗
PLN-101095 was shown to block the binding of cancer-associated fibroblasts (CAF) to the TGF-β latency-associated peptide (LAP) in a dose-dependent manner. |
| 2023-02-02 | Pliant Therapeutics, Inc. | Regulatory Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors pliantrx.com ↗ |
All press releases naming this drug 10 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLN-101095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06270706 ↗ |